Beneficial Effect of Vigconic VI-28 Capsule on Cyclophosphamide-Treated C57BL/6 Mice Carrying Lewis Lung Cancer Tumor
- VernacularTitle:Ⅵ-28胶囊辅助环磷酰胺治疗荷载LLC肿瘤小鼠的实验研究
- Author:
Ling ZHANG
;
Xiaowei BAI
;
Jingjing YANG
;
Lizhong WANG
;
Xiaoming GAO
- Publication Type:Journal Article
- Keywords:
VI-28;
chemotherapy;
tumor;
supplementary therapy
- From:
Chinese Journal of Cancer Biotherapy
1994;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate whether Vigconic VI-28 capsule, a formulated traditional Chinese medicine containing radix Ginseng, cornu cervi pantotrichum and semen cuscutae, can assist tumor chemotherapy in a mouse model. Methods: Female C57BL/6 mice were s. c. injected with viable Lewis lung cancer ( LLC) cells (106 cells/mouse) . The mice were then treated with cyclosposphamide (Cyp, 40 mg/kg bodyweight, once every other day). One group was intra-gastrically given 2% VI-28 (0.5 ml/mouse, every other day) during the course of the chemotherapy. By day 28, the mice were sacrificed and their thymic indices and tumor indices were calculated and compared. Splenocytes were collected for analysis of their immunological status. Histological study was carried to examine the solid tumors. Results: Fourteen days after the injection of LLC cells, solid tumors developed in most of the animals, reaching 1 ~ 1.8 cm diameters by 28 th day Compared with mice of the LCC + Cyp group, thymus glands from the LLC + Cyp + VI-28 group were significantly heavier. Splenocytes of the same group responded better to ConA stimulation in vitro. Histochemical examination of the tumor tissues revealed that tumors of the Cyp + VI-28 group were better differentiated (less aggressive) than that of the Cyp group. Conclusion: Vigconic VI-28 capsule can promote recovery of immune system in mice undergoing chemotherapy and help Cyp to control the growth of tumor cells in vivo.
